BACKGROUND AND OBJECTIVES: Renal elimination of amikacin and other aminoglycosides is slowed down in sepsis-induced acute kidney injury increasing the risk of adverse effects. Since neutrophil gelatinase-associated lipocalin (NGAL) and aminoglycosides share the mechanisms for renal excretion, the predictive power of NGAL was examined towards the changes in amikacin pharmacokinetics during early endotoxemia in anesthetized Wistar rats. METHODS: Endogenous biomarkers of inflammation and acute kidney injury were assessed including NGAL in saline-injected controls and two groups of rats challenged with an intravenous injection of bacterial lipopolysaccharide (5 mg/kg)-a fluid-resuscitated group (LPS) and a fluid-resuscitated group infused intravenously with 8 μg/kg/h terlipressin (LPS-T). Sinistrin and amikacin were infused to measure glomerular filtration rate (GFR) and amikacin clearance (CLam). The investigations included blood gas analysis, chemistry and hematology tests and assessment of urine output, creatinine clearance (CLcr) and sinistrin clearance (CLsini). RESULTS: Within 3 h of injection, systemic and renal inflammatory responses were induced by lipopolysaccharide. Gene and protein expression of NGAL was increased in the kidneys and the concentrations of NGAL in the plasma (pNGAL) and urine rose 4- to 38-fold (P < 0.01). The decreases in CLam and the GFR markers (CLcr, CLsini) were proportional, reflecting the extent to which endotoxemia impaired the major elimination mechanism for the drug. Terlipressin attenuated lipopolysaccharide-induced renal dysfunction (urine output, CLcr, CLsini) and accelerated CLam. The pNGAL showed a strong association with the CLsini (rs = - 0.77, P < 0.0005). Concerning prediction of CLam, pNGAL was comparable to CLcr (mean error - 24%) and inferior to CLsini (mean error - 6.4%), while the measurement of NGAL in urine gave unsatisfactory results. CONCLUSIONS: During early endotoxemia in the rat, pNGAL has a moderate predictive ability towards CLam. Clinical studies should verify whether pNGAL can support individualized dosing of aminoglycosides to septic patients.

Department of Biological and Medical Sciences Charles University Faculty of Pharmacy Akademika Heyrovského 1203 500 05 Hradec Králové Czech Republic

Department of Pharmacology Charles University Faculty of Medicine Hradec Králové Šimkova 870 500 38 Hradec Králové Czech Republic

Institute of Medical Biochemistry and Laboratory Diagnostics 1st Faculty of Medicine Charles University Prague and General University Hospital Prague U nemocnice 2 128 08 Praha 2 Czech Republic

Zobrazit více v PubMed

Crit Care Med. 2017 Aug;45(8):e821-e830 PubMed

Acta Physiol (Oxf). 2017 Mar;219(3):554-572 PubMed

Biometals. 2006 Apr;19(2):211-5 PubMed

Int Urol Nephrol. 2018 Apr;50(4):705-713 PubMed

Drugs. 2011 Dec 3;71(17):2277-94 PubMed

Intern Med J. 2011 Jun;41(6):441-9 PubMed

BMC Nephrol. 2012 Jun 27;13:25 PubMed

J Clin Pharmacol. 2016 Mar;56(3):307-15 PubMed

Antimicrob Agents Chemother. 1990 Apr;34(4):576-80 PubMed

Crit Care. 2009;13(4):R130 PubMed

Anal Biochem. 2001 Feb 1;289(1):10-7 PubMed

J Surg Res. 2014 May 15;188(2):503-9 PubMed

J Clin Invest. 2005 Mar;115(3):610-21 PubMed

J Leukoc Biol. 2007 Jan;81(1):137-43 PubMed

Crit Care Med. 2009 Mar;37(3):840-51; quiz 859 PubMed

Ann Lab Med. 2017 Sep;37(5):388-397 PubMed

Naunyn Schmiedebergs Arch Pharmacol. 2006 Jun;373(3):204-11 PubMed

Biomarkers. 2013 Jun;18(4):349-56 PubMed

Scand J Clin Lab Invest. 1995 Nov;55(7):577-88 PubMed

J Antimicrob Chemother. 2017 Jan;72(1):254-260 PubMed

Int J Antimicrob Agents. 2010 Dec;36(6):545-8 PubMed

PLoS One. 2015 Apr 20;10(4):e0124429 PubMed

Adv Chronic Kidney Dis. 2018 Jan;25(1):84-92 PubMed

Kidney Int. 2007 May;71(10):967-70 PubMed

Am J Physiol Renal Physiol. 2015 Mar 1;308(5):F388-99 PubMed

Drug Metab Pharmacokinet. 2004 Jun;19(3):159-70 PubMed

Crit Care. 2013 Mar 19;17(2):419 PubMed

Clin Pharmacokinet. 2017 Feb;56(2):127-138 PubMed